. Ther esearch interests in the group span areas such as enzyme inhibitors, new antibiotics, angiotensin II AT2R ligands,P ET tracers,p alladium catalysis, heterocycle synthesis,a nd the development of novel multicomponent reactions. In particular,s equential carbonylation and cyclization appealt ou sa saconvenient and straightforward synthetic route for the synthesis of heterocycles. The cover picture shows how carbon monoxide gas is diffused overab ridge, in the two-chamber system set-up used in this work, to take part in the catalytic cycle, and be incorporated into the heterocyclicc ore by ac arbonylation/cyclization domino reaction to yield 4H-benzo[e][1,3]oxazin-4-ones.F or more details, see the full text of the Full Paper
What aspects of this project do you find most exciting?
The most exciting aspecto ft his work is to provide an ew synthetic route towards benzoxazinones, which may be applied in, for example, small-scale drug discovery.T he fact that the synthesis works under CO atmospheresg enerated by am ultitude of CO sources, and even at atmosphericp ressure, is a reason why we believe this synthetic strategy will be highly attractive for synthetic and medicinal chemists.
What was the biggest surprise (on the way to the results presented in this paper)?
Theb iggest surprise wash ow difficulti tp rovedt ob et oi solate theprotected intermediate in ordertoclarify thereactionmechanism. We anticipated that thephenolwould be readilyprotected,b ys ilyl ethers or benzyl,f or example, andt hens tablei nt he carbonylation. However, it took severala ttemptsw ithd ifferent protective groups before the O-protected N-cyanobenzamideintermediate couldb ei solated, characterized, ands ubsequently deprotectedtocomplete thecyclisationprocess.
Is your current researchm ainly curiosity driven (fundamental) or rather applied?
The work described in this paper is purely driven by curiosity, and currently we are not workingo na ny applicationsf or benzoxazinones. However,m uch of the research we are conducting is applied towards finding novel antibacterial agents and developing new 11 C-labelled PET tracers.
